Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. reports clinical, corporate, and financing developments as a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other cancers. Olema Oncology updates commonly center on palazestrant (OP-1250), an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, and OP-3136, an orally available KAT6 inhibitor.
Recurring company news covers clinical and preclinical presentations at oncology meetings, endocrine-driven cancer biology, ER+/HER2- breast cancer studies, combination approaches with endocrine therapy and CDK inhibitors, operating results, public offerings, inducement equity grants, and board or management changes.
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on women's cancers, announced participation in two investor conferences this November. The events include the Jefferies London Healthcare Conference on November 16, 2021, at 5:00 p.m. GMT, and the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021, at 11:45 a.m. ET. Live webcasts will be available on Olema’s website and archived for 14 days. Olema’s lead product, OP-1250, targets ER-positive breast cancer and is currently undergoing clinical trials.
Olema Pharmaceuticals (Nasdaq: OLMA) announced a poster presentation on OP-1250, a dual action therapy for metastatic breast cancer, at the virtual AACR-NCI-EORTC Conference from October 7-10, 2021. The presentation will detail an ongoing Phase 1/2 study of OP-1250, a complete estrogen receptor antagonist and selective degrader, targeting ER-positive, HER2-negative breast cancer. Preliminary data from the trial's dose escalation phase is expected in Q4 2021. Olema focuses on women's cancers, with OP-1250 as its leading candidate.
Olema Pharmaceuticals (Nasdaq: OLMA) announced a poster presentation featuring preclinical data on OP-1250, a complete estrogen receptor antagonist and selective ER degrader. This data will be showcased at the 1st JCA-AACR Precision Cancer Medicine International Conference, occurring virtually from September 10-12, 2021. The presentation, titled "Complete Estrogen Receptor (ER) Antagonism As An Optimal Approach for ER-Positive Breast Cancer Drug Development," will be available on-demand on the conference website. The company aims to advance targeted therapies for women’s cancers.
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on targeted therapies for women's cancers, announced that Sean P. Bohen, M.D., Ph.D., CEO, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 4:15 p.m. ET. A live webcast will be available on Olema's website and archived for 14 days.
Olema’s lead candidate, OP-1250, is currently under evaluation for its effectiveness in treating ER-positive, HER2-negative breast cancer in a Phase 1/2 clinical trial.
Olema Pharmaceuticals reported significant advancements in its clinical trial for OP-1250, an investigational complete estrogen receptor antagonist, focusing on metastatic ER+/HER2- breast cancer. As of June 30, 2021, Olema holds $318.1 million in cash, expected to fund operations through 2023. The second quarter saw a net loss of $16.4 million, driven by increased R&D and G&A expenses, up from $1.9 million and $0.5 million, respectively, in the previous year. Importantly, 28 patients were enrolled in the Phase 1/2 trial, with interim data presentation anticipated in Q4 2021.
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on women’s cancers, announced that its CEO, Sean P. Bohen, will present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 3:00 p.m. ET. The presentation will be accessible via live webcast on Olema’s website, which will be archived for 14 days. Olema's lead candidate, OP-1250, is being evaluated in a Phase 1/2 trial for ER-positive, HER2-negative breast cancer.
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on women’s cancers, announced that CEO Sean P. Bohen will participate in a virtual fireside chat at the Jefferies 2021 Virtual Healthcare Conference on June 1, 2021, at 4:30 p.m. ET. The webcast will be available on Olema's website and archived for 14 days. Olema's lead candidate, OP-1250, is currently in a Phase 1/2 trial for ER-positive, HER2-negative breast cancer.
Olema Pharmaceuticals (Nasdaq: OLMA) reported progress in its Phase 1/2 trial of OP-1250 for ER+/HER2- breast cancer, with initial data expected in late 2021. The company holds $327 million in cash as of March 31, 2021, sufficient to fund operations through 2023. Q1 net loss was $15.3 million, up from $1.7 million year-over-year, with R&D expenses at $10.7 million due to heightened development activities. Olema appointed Yi Larson to its Board and strengthened R&D capabilities with new lab facilities in San Francisco.
Olema Pharmaceuticals (NASDAQ: OLMA) announced that its CEO, Sean P. Bohen, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2021, at 12 p.m. ET. The discussion will be moderated by Arlinda Lee, a Biotechnology Analyst at Canaccord Genuity. Investors can access a live webcast of the event in the Investors & Media section on Olema's website, with a replay available later. Olema is dedicated to developing targeted therapies for women’s cancers, including its lead candidate, OP-1250, currently in clinical trials.
Olema Pharmaceuticals has appointed Yi Larson to the Board of Directors amid advancements in its clinical development, particularly the OP-1250 program for breast cancer. Larson, previously CFO of Turning Point Therapeutics, brings extensive operational and healthcare banking experience. Frank McCormick, a longstanding director, transitions to Chair of the Scientific Advisory Board, continuing to advise Olema on its oncology strategies. This leadership shift aims to boost Olema's growth and pipeline expansion efforts focused on women’s cancers.